Compare

Sonova Holding AG/€SOON

1D1W1M3M6MYTD1Y5YMAX

About Sonova Holding AG

Sonova Holding AG is a Swiss company operating in the healthcare industry, specifically focusing on the development, manufacturing, and distribution of hearing care solutions. Its product portfolio includes hearing aids, cochlear implants, wireless communication devices, and professional audiological care services. Founded in 1947, Sonova is headquartered in Stäfa, Switzerland, and serves a global market with its products available in over 100 countries. The company distinguishes itself through continuous innovation in audiological technology and an integrated approach to hearing healthcare, providing both advanced products and comprehensive support services. Sonova’s strategic positioning is enhanced by its focus on research and development, as well as a robust distribution network that includes a mix of retail and wholesale channels.
Ticker
€SOON
Sector
Health
Primary listing
XGAT
Employees
18,580
Headquarters
Stäfa, Switzerland
Website
www.sonova.com

SOON Metrics

BasicAdvanced
€18B
38.97
€7.83
1.07
€5.10
1.67%

Bulls say / Bears say

Sonova grew FY 2025/26 sales by 5.9% and normalized EBITA by 17.3% in local currencies, with its hearing-instrument businesses gaining share. Management expects sales growth of 5–8% and core EBIT growth of 7–10% in FY 2026/27. (Sonova)
The new Phonak EON platform extends Sonova’s real-time AI hearing technology in a smaller, lighter device, which could help it win replacement and first-time buyers. Reuters reported that the launch is intended to strengthen the company’s competitive position and support growth. (Reuters)
Sonova’s growth opportunity in Asia may be material: Goldman Sachs said Japan sales grew 30–45% in the second half of FY 2026 and estimated that closing part of its Asian market-share gap could add about three percentage points to annual group revenue growth through FY 2027–29. (Yahoo Finance)
The cochlear-implant business remains a weak spot: FY 2025/26 sales fell 11.1% in local currencies, as China’s volume-based procurement changes and stronger competition weighed on the segment. Upgrade sales also declined as many users had already adopted the current processor. (Sonova)
Currency movements have obscured growth in reported results: despite local-currency sales growth, FY 2025/26 sales fell 0.2% in Swiss francs and reported EBITA fell 5.8%. Sonova also warned that exchange rates could reduce FY 2026/27 reported sales and core EBIT growth. (Sonova)
Valuation may limit further share-price gains: UBS cut its rating to Neutral after a 35% rally since July, arguing that the shares’ premium leaves limited upside relative to expected earnings growth. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.